AzTrials
AzTrials

ShockVoluKidNCT02666404

Impact of Amount of Fluid for Circulatory Resuscitation on Renal Function in Patients in Shock

A study testing Measurement in people with Shock, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

Volume resuscitation is the mainstay of treatment in most types of shock, especially in hemorrhagic and septic shock. Septic shock is a main cause of morbidity and mortality worldwide. Although there has been a lot of research to evaluate optimal amount and composition of fluids for volume resuscitation (e.g. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Shock
What is being tested?
Measurement
Could I receive a placebo?
No, everyone receives an active treatment
How many people
49 participants
Where
1 siteSwitzerland
Study dates
Jan 2016to 18 Mar 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age 18 years or older
  • State of shock (any type) upon admittance to the ICU.

Who cannot join

  • Age below 18 years
  • Non-shock state
  • Terminal state
  • Pregnancy
  • Jehovah's Witnesses

Trial locations and contacts

1 site in 1 country.

Switzerland1 site
  • University Hospital Basel

    Basel, 4031

Other trials in Switzerland

About this study

Official title: Impact of Amount of Fluid for Circulatory Resuscitation on Renal Function in Patients in Shock: Evaluating the Combination of Intraabdominal Pressure and Renal Resistive Index With Hemodynamic Parameters for Guidance of Shock Therapy - A Multicenter International Clinical Trial

Volume resuscitation is the mainstay of treatment in most types of shock, especially in hemorrhagic and septic shock. Septic shock is a main cause of morbidity and mortality worldwide. Although there has been a lot of research to evaluate optimal amount and composition of fluids for volume resuscitation (e.g. colloids, crystalloids, red blood cell transfusion, albumin, fresh frozen plasma) particularly in the past decade, results remain inconclusive and to some extent contradictive. The investigators would like to contribute to the establishment of new endpoints for the guidance of shock therapy focusing on the first 24 and 48 hours, amending the currently used parameters (i.e. cardiac output, heart rate, blood pressure, central venous pressure) with new measurements (see study specific measurements). The goal is to decrease the need for renal replacement therapy, thereby eventually reducing patient morbidity and mortality.

Read the detailed description

Background and Rationale, clinical evidence to date:

All forms of shock and especially septic shock, in which tissue metabolic demands are not fulfilled by blood supply, are main causes of morbidity and mortality worldwide and develops in one third of the patients admitted to the ICU. Not only is this high incidence alarming, the uncertainty about the undeceiving parameters for guidance of fluid resuscitation to not only avoid acute kidney injury and renal replacement therapy but also the consequences of fluid overload, such as interstitial pulmonary edema, underline the importance of further research within this field. This is why the investigators would like to contribute to the establishment of new parameters for the guidance of shock therapy focusing on the first 72 hours, amending the currently used parameters (i.e. cardiac output, heart rate, blood pressure, central venous pressure) with new measurements, including assessment of total body water, renal vascular resistance (renal resistive index (RRI)) and microcirculatory blood flow.

Although the application of intravenous crystalloid fluids, red blood cell concentrates in anemia, and catecholamines or inotropes are the mainstay of shock therapy, no clear endpoints for the fluid resuscitation or the hemodynamic endpoints for catecholamine therapy have been established so far. Static parameters such as central venous or arterial pressure, cardiac output, or plasma lactate failed in the guidance of the amount of fluid administered. The administration of intravenous fluids in response to so-called dynamic tests, such as stroke volume variation in response to fluid bolus administration, also did not show an influence on organ dysfunction and mortality due to shock. Acute kidney injury (AKI) is the most frequent organ dysfunction in patients in shock. Despite a more aggressive early fluid resuscitation and correction of arterial blood pressure, the incidence of AKI does not seem to decrease. One possible reason is that the excessive amount of fluid administered to these patients for hemodynamic stabilization and maintenance of urinary output harm kidney function. Indeed, a correlation between total amount of fluid administered, high central venous pressure, organ dysfunction, and mortality has been shown in patients with severe sepsis and septic shock. Established static and dynamic hemodynamic parameters are not influenced by the severity of capillary leakage and microcirculatory impairment due to inflammation-induced injury in capillaries. The relatively low perfusion pressure together with interstitial edema, microcirculatory injury, and a high outflow pressure may harm renal function by a decreased glomerular urine excretion. Intraabdominal pressure, total body water, and central venous pressure together with the renal resistive index may be additional measurements to reduce the rate of acute kidney injury and to guide fluid therapy in shock.

The goal of the present study is to refine fluid resuscitation endpoints with new measurements to administer the optimal amount of fluid with the smallest possible adverse effects. Complexity of therapy in severe sepsis and septic shock as well as in other shock states was the topic of numerous studies showing no benefit of advanced macro-circulatory parameters for guidance of fluid resuscitation in shock. If the chosen measurements are unable to establish new endpoints for guidance in shock therapy, the investigators' research might be expanded to the evaluation of future therapies, such as biomarkers or stem cells. After establishment of more regional resuscitation endpoints, the investigators plan to evaluate these endpoints in a randomized, controlled setting against established hemodynamically-guided shock therapy.

Investigational measurements:

The investigators will perform the following new measurements and assessments for guidance of fluid resuscitation at 0, 6, 24, 48, and 72 hours after shock diagnosis and concomitant fulfillment of eligibility requirements:

Patient characteristics:

  • Sepsis-related Organ Failure Assessment (SOFA) score, daily
  • APACHE II score, first 24 hours
  • Simplified Acute Physiology (SAPS) II score, first 24 hours

Established parameters:

  • Hemodynamic parameters (cardiac index [5], central venous pressure, blood pressure, heart rate, central/mixed venous oxygen saturation = ScvO2/venous oxygen saturation (SvO2), pulmonary capillary occlusion pressure (PAOP)
  • Use of inotropic and vasoactive drugs (epinephrine, norepinephrine, milrinone, dobutamine, levosimendan)
  • Laboratory parameters (lactate, sodium, potassium, blood sugar concentration and need for insulin therapy with respect to need for immunosuppressive therapy)
  • Parameters of renal function (creatinine, creatinine clearance, blood urea nitrogen, urine output, potassium, urinary protein, urinary sediment analysis, sodium excretion fraction, need for renal replacement therapy)
  • Creatinine clearance after 24, 48, and 72 hours
  • Urinary sediment analysis 72 hours
  • Urinary protein screening after 72 hours

Fluid administration:

  • Total amount of fluids (ml) administered
  • Total amount of crystalloids (ml) administered after onset of shock symptoms
  • Total amount of colloids (ml) administered
  • Amount of red blood cell and plasma transfusion
  • Amount of albumin infusion

Alternative parameters influenced by severity of capillary leakage and microcirculatory injury:

  • Renal artery resistive index (Doppler analysis)
  • Intra-abdominal pressure (bladder pressure management)
  • Total body water (bio-impedance analysis): this is a commonly used method for assessment of body composition
  • Microcirculatory blood flow (CytoCam incident dark-field illumination): "hand-held device (…), providing new means of directly visualizing the microcirculation and evaluating the effects of interventions on microcirculatory flow in easily accessible surfaces"

Outcome parameters:

  • Acute kidney injury according to 'Kidney Disease: Improving Global Outcomes' (KDIGO) criteria
  • Need for renal replacement therapy
  • Length of intensive care stay
  • Length of hospital stay

Safety: risks and benefits:

Since the investigators are only performing noninvasive measurements, additional to interventions, pharmacotherapy and measurements in shock patients, there will be no contributing risk by study enrolment. Since there will be a more precise way for guidance of fluid resuscitation in shock evoked by these study-specific measurements (bio-impedance analysis, doppler analysis, CytoCam incident darkfield illumination), study patients might even benefit from enrolment.

Conditions
Shock
Being tested
Measurement
Keywords
Volume Resuscitation, Shock, Body Impedance Measurement, Renal Resistive Index, Acute Kidney Injury, Renal Replacement Therapy
Medical subject headings
Shock, Acute Kidney Injury

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MeasurementOther

    Also called Body Impedance Measurement, Renal Resistive Index, Intra-abdominal Pressure

    We will perform those new measurements and assessments for guidance of fluid resuscitation at 0, 6, 24, 48, and 72 hours after shock diagnosis and concomitant fulfillment of eligibility requirements

Study groups in NCT02666404
Study groupRoleWhat they receive
Volume ResuscitationExperimentalWe would like to establish new endpoints for guidance of volume resuscitation by implementing new measurements (body impedance, renal resistive index).
Receives: Other: Measurement

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Acute kidney injury (KDIGO staging for severity of acute kidney injury ).

    Change in renal function from baseline according to KDIGO staging

    Measured: Assessment at 0, 6, 24, 48, and 72 hours after shock diagnosis

Secondary outcomes (6)
  1. Difference in lactate values (µmol/l)

    Measured: Between 6 and 24 hours after admittance to the ICU and baseline (t1/t2 - t0)

  2. Need for renal replacement therapy (KDIGO staging for severity of acute kidney injury)

    Measured: Assessment at 0, 6, 24, 48, and 72 hours after shock diagnosis

  3. Length of ICU stay

    If Patient stay exceeds one month, we will assess the data at intervals of one month

    Measured: 1 month

  4. Length of hospital stay

    If Patient stay exceeds one month, we will assess the data at intervals of one month

    Measured: 1 month

  5. Need for mechanical ventilation

    Measured: During 27 hours

  6. In-hospital, 30-, and 90-day mortality

    Measured: 0-90 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Jan 2016 (estimated)
  2. Study startJan 2016
  3. Primary completion18 Mar 2021
  4. Study completion18 Mar 2021

Why it stopped: Volume resuscitation procotol has changed around 2017/2018 to less volume/more vasopressors.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
49 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02666404
Sponsor's protocol ID
EKNZ 2015-401
Acronym
VoluKid
Status last verified
Mar 2021
First submitted
18 Jan 2016
Last updated
1 Apr 2021
Results posted
No
Data monitoring committee
Yes
Individual data sharing
Yes: Average Acute Physiology And Chronic Health Evaluation (APACH) II score/SAPS II score/SOFA score/KDIGO criteria

Questions about this trial

What is this clinical trial studying?

A study testing Measurement in people with Shock, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 1 Apr 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: Volume resuscitation procotol has changed around 2017/2018 to less volume/more vasopressors.). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Acute kidney injury (KDIGO staging for severity of acute kidney injury ). (time frame: Assessment at 0, 6, 24, 48, and 72 hours after shock diagnosis). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Apr 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in